Inositol in the EU: Novel Food Status and Claims

Inositol is one of the easier categories to sell in the EU – and one of the easiest to get wrong on the label. The short version: myo-inositol and D-chiro-inositol are not Novel Foods when used in food supplements, the 40:1 blend of the two inherits that status, and neither isomer has an authorised EFSA health claim. That combination means you can place the ingredient on the market, but the wording around it has to be handled carefully. This guide sets out the rules, the wording that survives review, and the documents an EU buyer will ask for.

The Three Rules That Decide Whether a SKU Can Ship

  • Directive 2002/46/EC treats food supplements as food, not medicine. Vitamins and minerals are regulated through positive lists; “other substances” such as inositol are left to national rules, which is why member-state positions matter.
  • Regulation 1924/2006 governs health claims. A claim must either be authorised in the EU register or sit in the on-hold list under transitional measures. Disease prevention, treatment and cure claims are prohibited outright.
  • Regulation 2015/2283 governs Novel Foods – anything not consumed to a significant degree in the EU before 15 May 1997 needs pre-market authorisation. This is the rule that decides whether an ingredient can enter at all.

Novel Food Status for the Inositol Family

Ingredient EU Novel Food position Practical consequence
Myo-inositol (CAS 87-89-8) Not a Novel Food Can be used in food supplements without a Novel Food authorisation
D-chiro-inositol (CAS 643-12-9) Not a Novel Food; the European Commission’s 2025 clarification removed the earlier uncertainty Usable in food supplements; keep the clarification in your compliance file
40:1 myo/DCI blend Both components are non-Novel, so the blend is not a Novel Food No authorisation needed for the blend itself; document both assays

Two caveats belong next to that table. The EU Novel Food Catalogue is a reference tool, not a binding legal act – the final call sits with the member state where the product is placed on the market. And the status above applies to food supplement use; moving the same ingredient into a conventional food or a beverage changes the analysis and should be checked separately.

What You Can and Cannot Say

Because no inositol health claim is authorised, the label and the e-commerce copy carry the real risk. The table below is the practical dividing line.

Type of statement Example Status
Composition / identity “2,000 mg myo-inositol and 50 mg D-chiro-inositol per serving” Factual, not a health claim
Structure / function description “Myo-inositol is a carbocyclic sugar alcohol involved in cell signalling” Acceptable as description, but stops being description the moment it promises an outcome
On-hold health claim Wording carried over from the on-hold list Transitional use only; member-state dependent; not “approved”
Disease claim “treats PCOS”, “helps insulin resistance”, “prevents diabetes” Prohibited under 1924/2006

The trap in this category is that the research language is disease language. Papers discuss polycystic ovary syndrome and metabolic markers, so marketing teams copy the vocabulary. On a label or a product page in the EU, that vocabulary is a claim – and an unauthorised one. Keep the clinical context in your internal file and keep the consumer-facing text at the level of composition and traditional or on-hold wording.

The Label Checklist

Under Regulation 1169/2011 and Directive 2002/46/EC, a food supplement label in the EU carries:

  • The product name with the words “Food supplement” (in the language of the market).
  • The name of the characteristic ingredient or substances – here, both isomers, stated separately.
  • The recommended daily portion.
  • A warning not to exceed the stated daily dose.
  • A statement that food supplements are not a substitute for a balanced diet.
  • Keep out of reach of young children.
  • Nutrient content as a percentage of the reference intake (NRV) where an NRV exists.
  • No wording attributing prevention, treatment or cure of a disease.

For a 40:1 blend, add one more discipline: state the ratio on the label only if the batch COA can prove it. A ratio printed on pack is a quantitative claim about composition, and it is the first thing a competent authority will test.

Documentation an EU Buyer Will Ask For

  • Specification sheet and batch COA with separate assays for myo-inositol and D-chiro-inositol, plus the calculated ratio.
  • Heavy metals, microbiology, ethylene oxide, PAH and pyrrolizidine alkaloid results.
  • Pesticide residue statement against EU MRLs (EC) 396/2005.
  • Non-GMO and allergen statements; MSDS.
  • A written note on the Novel Food status you are relying on, with the date it was checked.
  • GMP or ISO evidence for the manufacturing site.

Core Nutrix supplies myo-inositol and D-chiro-inositol with this document set per batch, including EU MRL pesticide screening and Prop 65 statements. If you need the ratio locked before shipping, the 40:1 premix guide covers how that is verified.

Member-State Reality Check

Most member states require a pre-market notification for food supplements, and the timelines vary – Ireland, for example, runs a review that can take months. Mutual recognition generally allows a product lawfully sold in one member state to move into another, but plant-based and “other substance” categories can be overridden by national positive or negative lists. In practice, the sequence that works is: settle the formulation and the label in one demanding market (Germany or the UK are common starting points), then extend country by country with the notification file already built.

← Back to all guides

40:1 Premix Buying Guide  Request Free Samples  Contact Us

Frequently Asked Questions (FAQ)

Is D-chiro-inositol a Novel Food in the EU?

No. The European Commission’s 2025 clarification places D-chiro-inositol outside the Novel Food scope for food supplement use, which resolved the earlier uncertainty in markets such as Spain. Confirm the current catalogue entry for your destination market before launch.

Is myo-inositol a Novel Food?

No. Myo-inositol has a long history of use in the EU and is not treated as a Novel Food.

Does the 40:1 blend need its own Novel Food authorisation?

No. Both components are non-Novel and blending is a process, not a new ingredient. The blend still needs a specification and a COA that prove the ratio.

Can we say inositol “supports hormonal balance”?

Not as an authorised claim – no inositol health claim is in the EU register. Any wording that promises a health outcome is a health claim under 1924/2006 and needs an authorised or on-hold basis. Composition statements and factual descriptions are the safe ground.

What is an “on-hold” claim?

A claim that was submitted for assessment but not yet decided. It may be used under transitional measures in some member states, but it is not approved and it is not a safe assumption across the EU.

Do we need a Novel Food statement from the supplier?

It is not a legal document, but EU buyers routinely ask for a written position on Novel Food status with a check date. We provide one with the batch documents.

Leave a Comment or Ask a Question

No account or email needed - just enter a display name. We answer questions within 24 hours.

Scroll to Top